The payers' perspective on gene therapies.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Drivers of managed entry agreements to reduce reimbursement challenges of orphan medicinal products: the development of a matrix.Orphanet journal of rare diseases · 2025
   Pooled it
2. The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects.Drug discovery today · 2021
   Review
3. Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies.Frontiers in pharmacology · 2020
   Review
4. Assessing the Joint Value of Genomic-Based Diagnostic Tests and Gene Therapies.Journal of personalized medicine · 2019
   Article
5. DNA Delivery Systems Based on Peptide-Mimicking Cationic Lipids-The Effect of the Co-Lipid on the Structure and DNA Binding Capacity.Langmuir : the ACS journal of surfaces and colloids · 2019
   Article
6. The state of gene therapy research in Africa, its significance and implications for the future.Gene therapy · 2017
   Review
7. Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects.Journal of inherited metabolic disease · 2017
   Review
8. Ethical Hurdles in the Prioritization of Oncology Care.Applied health economics and health policy · 2017
   Article
9. Genome editing and the next generation of antiviral therapy.Human genetics · 2016
   Review

Corrections and comments

• Comment on
  The special case of gene therapy pricing.2014

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as